Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic antibody expression technology.

H E Chadd1, S M Chamow

  • 1Department of Process Sciences, Abgenix Inc, 6701 Kaiser Drive, Fremont, CA 94555, USA. chadd_h@abgenix.com

Current Opinion in Biotechnology
|April 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.

Biochemistry·2001
Same author

Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.

Journal of cellular biochemistry·1999
Same author

A simple, two-component buffer enhances use of chromatofocusing for processing of therapeutic proteins.

Biotechnology and bioengineering·1999
Same author

A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production.

Journal of immunology (Baltimore, Md. : 1950)·1998
Same author

Immunoadhesins as research tools and therapeutic agents.

Current opinion in immunology·1997
Same author

Identification of iron superoxide dismutase and a copper/zinc superoxide dismutase enzyme activity within the marine cyanobacterium Synechococcus sp. WH 7803.

FEMS microbiology letters·1996
Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026
Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026
Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026
Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026
Same journal

Harvesting insights from recent advances in yeast genomics for predictable and precision wine fermentation.

Current opinion in biotechnology·2026
Same journal

Minimal enzyme cascades for the aromatic-to-aromatic upgrading of lignin monomers.

Current opinion in biotechnology·2026
See all related articles

Antibodies are increasingly vital biotherapeutics for treating cancer, inflammation, and cardiovascular diseases. Mammalian cell culture and transgenic organisms are promising for full-length antibody production, while bacterial systems excel at producing antibody fragments.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Antibodies have emerged as a significant class of biotherapeutics due to technological advancements.
  • Genomic discoveries reveal new therapeutic targets, enhancing the potential of antibody-based treatments.

Purpose of the Study:

  • To review the potential of antibodies as therapeutics in oncology, inflammation, and cardiovascular disease.
  • To evaluate different expression systems for producing full-length antibodies and antibody fragments.

Main Methods:

  • Exploration of expression systems including mammalian cells, bacterial cells, and transgenic organisms.
  • Consideration of factors such as molecular fidelity and cost of goods in system evaluation.

Main Results:

Related Experiment Videos

  • Mammalian cell culture and transgenic organisms demonstrate significant promise for expressing full-length recombinant human antibodies.
  • Bacterial fermentation appears to be the most favorable system for expressing antibody fragments.

Conclusions:

  • The full therapeutic potential of antibodies in oncology, inflammation, and cardiovascular disease is being realized.
  • Optimized expression systems are crucial for the efficient and cost-effective production of antibody therapeutics.